Pharmacotherapy for erectile dysfunction

Expert Opinion on Investigational Drugs

Volumn 17, Issue 5, 2008, Pages 679-690

  Feifer, Andrew ^a   Carrier, Serge ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Apomorphine; Erectile dysfunction; Gene therapy; Melanocortin; Pharmacotherapy; Phosphodiesterase inhibitors; Potassium channel; Rho kinase; sGC activators

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; 1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; 5 FLUORO 2 [[4 (2 PYRIDINYL) 1 PIPERAZINYL]METHYL] 1H INDOLE; ABT 724; ALPHA 1 ADRENERGIC RECEPTOR; APOMORPHINE; AVAFANIL; BETA INTERMEDIN[11-22][11 (N ACETYLCYSTEINE) 14 [3 (2 NAPHTHYL) DEXTRO ALANINE] 18 CYSTEINE 22 ASPARTIC ACID AMIDE] 11,18 CYCLIC DISULFIDE; CORTICOTROPIN; CP 226269; CYTOCHROME P450 3A4; DOPAMINE RECEPTOR STIMULATING AGENT; GUANYLATE CYCLASE ACTIVATOR; MELANOCORTIN; N [4 (2 CYANOPHENYL) 1 PIPERAZINYLMETHYL] 3 METHYLBENZAMIDE; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; N ACETYLNORLEUCYLASPARTYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHYLLYSINE 2,7 CYCLIC AMIDE; NAKED DNA; PHOSPHODIESTERASE INHIBITOR; PHU 142774E; PINACIDIL; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; RHO KINASE INHIBITOR; SILDENAFIL; TADALAFIL; UDENAFIL; UNINDEXED DRUG; VARDENAFIL; CELL RECEPTOR; GUANYLATE CYCLASE; RHO KINASE; SOLUBLE GUANYLYL CYCLASE;

ALCOHOL CONSUMPTION; BRADYCARDIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORPUS CAVERNOSUM; DIET; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; EX VIVO GENE TRANSFER; EXERCISE; HEADACHE; HUMAN; IN VIVO GENE TRANSFER; LIFESTYLE MODIFICATION; LOW DRUG DOSE; NAUSEA; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PENILE BLOOD FLOW; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING; SOCIOECONOMICS; SYNCOPE; TESTOSTERONE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VASODILATATION; ANIMAL; DRUG ANTAGONISM; GENE THERAPY; GENETICS; MALE; METABOLISM;

ANIMALS; DOPAMINE AGONISTS; ERECTILE DYSFUNCTION; GENE THERAPY; GUANYLATE CYCLASE; HUMANS; MALE; MELANOCORTINS; PHOSPHODIESTERASE INHIBITORS; POTASSIUM CHANNEL BLOCKERS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RHO-ASSOCIATED KINASES;

EID: 44449122445     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.5.679     Document Type: Review

References (116)

1. Jardin A, Wagner G, Khoury S, et al. Recommendations of the first international consultation on erectile dysfunction. In: Jardin A, Wagner G, Khoury S, et al., editors, Erectile dysfunction. Plymouth, UK: Health Publications Ltd; 2000. p. 711-26
2. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90
3. Brock GB, Lue TF. Drug-induced sexual dysfunction: an update. Drug Saf 1993;8:414-26
4. Mulcachy JJ. Erectile dysfunction - is the incidence increasing? [editorial]. J Urol 2000; 163:471
5. Kleinman KP, Feldman HA, Johannes CB, et al. A newsurrogate variable for erectile dysfunction status in the Massachusetts Male Aging Study. J Clin Epidemiol 2000;53(1):71-8
6. Brock G. Erectile dysfunction update education forum summary. Can J Urol 2000;8:1416-8
7. Holmquist F, Steif CM, Jonas U, Anderson KE. Effects of the nitric oxide synthase inhibitor Ng-nitro-L arginineon the erectile response to cavernous nerve stimulation in the rabbit. Acta Phys Scand 1991;143:229-304
8. Holmquist F, Hedlund H, Anderson KE. Ng-nitro-L arginine inhibits non-adrenergic, non-cholinergic relaxation of human isolated corpus cavernosum. Acta Physiol Scand 1991;141:441-2
9. Ignarro LJ, Bush PA, Buga GM, et al. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990;170:943-50
10. Stief CG, Uckerert S, Becker AJ, et al. The effect of the specific phosphobdiesterase (PDE) inhibitors on human and rabbit cavernous tissue invitro and in vivo. J Urol 1998;159(4):1390-3
11. Bancroft J, Wu FCW. Changes in erectile responsiveness during androgenreplacement therapy. Arch Sex Behav 1983;12:59-66
12. Kwan M, Greenleaf WJ, Mann J, et al. The nature of androgenaction on male sexuality: a combined laboratory/self-reported study on hypogonadal men. J Clin Endocrinol Metab 1983;57(3):557-62
13. Saenz de Tejada I, Blanco R. Goldstein I, et al. Cholinergic neurotransmission in human corpus cavernosum. I. Response of isolated tissue. Am J Physiol 1988;254(3 Pt 2):H459-67
14. Rampin O, Giuliano F. Brain control of penile erection. J Urol 2001;19(1):1-8
15. Giuliano F, Allard J. Apomorphine SL (Uprima): preclinical and clinical experiences learned from the first central nervous system-acting ED drug. Int J Impot Res 2002;14(Suppl 1):S53-6
16. Kaiser FE, Viosca SP, Morley JE, et al. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc 1988;36:511-9
17. Andersson K-E. Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J Urol 2003;170:S6-14
18. Gonzalez-Cadavid NF, Rajfer J. Therapy of erectile dysfunction. Endocrine 2004;23(2-3):167-76
19. Bors E, Comar AE. Neurological urology; physiology of micturition, its neurological disorders and sequelae. Baltimore: University Park Press; 1971
20. Walsh PC. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CAPSURE. J Urol 2000;163(1):370
21. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, et al. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the epidemiologia de la disfuncion erectila masculina study. J Urol 2001;166:569-74
22. McVary KT, Carrier S, Wessells H. Subcommittee on smoking and erectile dysfunction socioeconomic committee, sexual medicine society of North America. Smoking and erectile dysfunction: evidence based analysis. J Urol 2001;166(5):1624-32
23. Fazio L, Brock G. Erectile dysfunction: management update. CMAJ 2004;170(9):1429-37
24. Nickel JC, Morales A, Condra M, et al. Endocrine dysfunction. In impotence: incidence, significance, and cost-effective screening. J Urol 1984;132(1):40-3
25. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 2000;163(2):460-3
26. Montorsi F, Briganti A, Salonia A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003;44:360-5
27. Thompson IM, Tangen CM, Goodman PJ, et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294(23):2996-3002
28. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Proc Nucleic Acid Res Mol Biol 2001;65:1-52
29. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995;75:725-48
30. Saenz de Tejada I, Angulo J, Cuevas P, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardena® I. Int J Impot Res 2001;13:282-90
31. Kang K, Yu J, Yoo M, Kwon JW. The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction. Int J Impot Res 2005;17:409-16
32. Vivus, Inc. Mountain view, CA, USA, data on file. VIVUS announced positive data from a Phase II at-home, multicenter, double-blind, randomized, parallel-design study conducted to assess the safety and efficacy of different doses of avanafil for the treatment of ED. Available from: www.vivus.com
33. Hatzimouratidis K, Hatzichrisrou DG. Looking to the future for erectile dysfunction therapies. Drugs 2008;68(2):231-50
34. Heaton JP, Morales A, Adams MA, et al. Recovery of erectile function by the oral administration of apomorphine. Urology. 1995;45:200-6
35. Fagan TC, Buttler S, Marbury, et al.; Apomorphine Study Group. Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates. Am J Cardiol 2001;88:760-6
36. Altwein JE, Keuler FU. Oral treatment of erectile dysfunction with apomorphine SL. Urol Int 2001;67:257-63
37. Pehek EA, Thompson JT, Hull EM. The effects of intracranial administration of the dopamine agonists apomorphine on penile reflexes and seminal emission in the rat. Brain Res 1989;(500):325-32
38. Dula E, Keating W, Siami PF, et al. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group. Urology 2000;56:130-5
39. Hull EM. Dopaminergic influences on male rat sexual behavior. In: Micevych PE, Hammer R, editors, Neurobiological effects of sex steroid hormones. University Press, Cambridge; 1995. p. 234-53
40. Dehpour AR, Samini M, Sharifzadeh M, Hasan-Mazandarani H. Effects of chronic lithium pretreatment on apomorphine-induced penile erection. Gen Pharmacol 1995;26:1015-20
41. Peana AT, D'Aquila PS, Chessa ML, et al. (-)-Linalool produces antinociception in two experimental models of pain. Eur J Pharmacol 2003 26;460(1):37-41
42. Zarrindast MR, Shokravi S, Samini M. Opposite influences of dopaminergic receptor subtypes on penile erection. Gen Pharmacol 1992;23:671-5
43. Schulman C, Sleep DJ. Duration of erectile dysfunction prior to treatment influences the response to apomorphine SL. Annual Meeting of the American Urological Association; 2002 May 25-30; Orlando, USA
44. Gontero P, D'Antonio R, Pretti G, et al. Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men. Drugs 2004;64(23):2667-88
45. Athanasopoulos A, Barbalias G. A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. J Impot Res 2004;16(1):2-7
46. Eardley J, Wright P, MacDonagh R, et al. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004;93(9):1271-5
47. Yongon-dong CG. Potentiation of apomorphine effect on sildenafil-induced penile erection in conscious rabbits. Asian J Androl 2004;6(3):205-9
48. Strebel RT, Reitz A, Tenti G, et al. Apomorphine sublingual as primary or secondary treatment for erectile dysfunction in patients with spinal cord injury. BJU Int 2004;93(1):100-4
49. Mulhall J. Sublingual apomorphine for the treatment of erectile dysfunction. Expert Opin Investig Drugs 2002;11:295-302
50. Brioni JD, Moreland RB, Cowart M, et al. Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci USA 2004;101(17):6758-63
51. Stephenson DT, Meglasson MD, Connell MA, et al. The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys. J Pharmacol Exp Ther 2005;314(3):1257-66
52. Somlyo AP, Somlyo AV. From pharmacomechanical coupling to G-proteins and myosin phosphatase. Acta Physiol Scand 1998;164:437-48
53. Rees RW, Ziessen T, Ralph DJ, et al. Human and rabbit cavernosal smooth muscle cells express Rho-kinase. Int J Impot Res 2002;14:1-7
54. Wang H, Eto M, Steers WD, et al. RhoA-mediated Ca2 sensitization in erectile function. J Biol Chem 2002;277:30614
55. Rees RW, Ziessen T, Ralph DJ, et al. Human and rabbit cavernosal smooth muscle cells express Rho-kinase. Int J Impot Res 2002;14:1
56. Fu X. The effects of the Rho-kinase inhibi tor Y-27632 on arachidonic acid-, GTPgammanS-, and phorbol ester-induced Ca2b-sensitization of smooth muscle. FEBS Lett 1998;440:183-7
57. Chitaley K, Wingard CJ, Clinton Webb R. et al. Antagonism of Rho-kinase stimulates rat penile erection via 2 nitric oxide-independent pathway. Nat Med 2001;7:119-22
58. Chitaley K, Bivalacqua TJ, Champion HC, et al. Adeno-associated viral gene transfer of dominant negative RhoA enhances erectile function in rats. Biochem Biophys Res Commun 2002;298:427
59. Dai Y, Pollock DM, Lewis RL, et al. Receptor-specific influence of endothelin-1 in the erectile response of the rat. Am J Physiol Regul Integr Comp Physiol 2000;279:R25
60. Argiolas A, Melis MR, Murgia S, Schioth HB. ACTH and alpha-MSH induced grooming, stretching, yawning and penile erection in male rats: site of action in the brain and role of melanocortin receptors. Brain Res Bull 2000;51:425-31
61. Bischoff E, Schramm A, Straub A, et al. BAY 41-2272: a stimulator of soluble guanylate cyclase induces nitric oxide dependent penile erection in vivo. Urology 2003;61(2):464-7
62. Bertolini A, Gessa GL, Ferrari C. Penile erection and ejaculation: a central effect of ACTH-like peptides in mammals. In: Sandler M, Gessa GL, editors, Sexual behavior: pharmacology and biochemistry. New York: Raven Press; 2001. p. 247-57
63. Giuliano F, Rampin O. Central neural regulation of penile erection. Neurosci Biobehav Rev 2000;24:517-33
64. Wessells H, Hruby VJ, Hackett J, et al. Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2 induces penile erection via brain and spinal melanocortin receptors. Neuroscience 2003;118:755-62
65. Melman A, Bar-Chama N, McCullough A, Davies K. Christ the first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results. Eur Urol 2005
66. Vemulapalli R, Kurowski S, Salisbury B, et al. Activation of central melanocortin receptors by MT-II increases cavernosal pressure in rabbits by the neuronal release of NO. Br J Pharmacol 2001;134:1705-10
67. Hsieh GC, Hollingsworth PR, Martino B, et al. Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine. J Pharmacol Exp Ther 2004;308(1):330-8
68. Vergoni AV, Bertolini A, Mutulis F, et al. Differential influence of a selective melanocortin MC4 receptor antagonist (HS014) on melanocortin-induced behavioral effects in rats. Eur J Pharmacol 1998;362:95-101
69. Dines KC, Gahman TC, Girten BE, et al. Melanocortin receptor-3 ligands to treat sexual dysfunction. US653450; 2003
70. Van der Ploeg LH, Martin WJ, Howard AD, et al. A role for the melanocortins 4 receptor in sexual Function. Proc Natl Acad Sci USA 2002;99:11381-6
71. Martin WJ, McGowan E, Cashen DE, et al. Activation of melanocortins MC-4 receptors increases erectile activity in rats ex copula. Eur J Pharmacol 2002;454:71-9
72. Gonzalez-Cadavid NF, Burnett AL. Magee TR, et al. Expression of penile neuronal nitric oxide synthase variants in the rat and mouse penile nerves. Biol Reprod 2000;63(3):704-14
73. Mizusawa H, Hedlund P, Andersson KE. Alpha-melanocyte stimulating hormone and oxytocin induced penile erections, and intracavemous pressure increases in the rat. J Urol 2002;167:757-60
74. Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-1 clinical study. Life Sci 1996;58:1777-84
75. Wessells H, Gralnek D, Dorr R, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 2000;56:641-6
76. Chicaley K, Bivalacqua TJ, Champion HH, et al. Adeno-associated viral gene transfer of dominant negative RhoA enhances erectile function in rats. Biochem. Biophys Res Commun. 2002;298:427-32
77. Molinoff PB, Shadiack AM, Earle D, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann NY Acad Sci 2003;994:96-102
78. Bakircioglu ME, Lin CS, Fan P, et al. The effect of adeno-associated virus mediated brain derived neurotrophic factor in an animal model of neurogenic impotence. J Urol 2001;165(6 Pt 1):2103-9
79. Luca:s KA, Pitari GM, Kazerounian S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000;52:375
80. Lue TF. Erectile dysfuncton. N Engl J Med 2000;342:1802
81. Yu SM, Cheng ZJ, Guh JH, et al. Mechanism of antiproliferation caused by YC- 1, an indazole-derivative, in cultured rat A10 vascular smooth-muscle cells. Biochem J 1995;306:787
82. Stasch JP, Becker EM, Alonso-Alija C, et al. NO independent regulatory site on soluble guanylate cyclase. Nature 2001;410:212
83. Friebe A, Koesling D. Mechanism of YC-1 -induced activation of soluble guanylyl cyclase. Mol Pharmacol 1998;53:123
84. Lee YC, Martin E, Murad F. Human recombinant soluble guanylyl cyclase: expression, purification and regulation. Proc Natl Acad Sci USA 2000;97:10763
85. Wohlfart P, Malinski T, Ruetten H, et al. Release of nitric oxide from endothelial cells stimulated by YC- 1, an activator of soluble guanylyl cydase. Br J Pharmacol, 1999;128:1316
86. Hsieh GC, O'Neill AB, Moreland RB, et al. YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats. Eur J Pharmacol 2003;458:183-9
87. Ghersa A, Pescini GF, Sartonet-Roche. P, et al. Highly controlled gene expression using combinations of a tissue-specific promoter, recombinant adenovirus and a tetracycline-regulatable transcription factor. Gene Ther 1998;5(9):1213-20
88. Wohlfart P, Malinski T, Ruetten H, et al. Release of nitric oxide from endothelia Icells stimulated by YC-1, an activator of soluble guanylyl cyclase. Br J Pharmacol 1999;128:1316
89. Galle J, Zabel U, Hübner U, et al. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 1999;127:195-203
90. Mizusawa H, Hedlund P, Brioni JP, et al. Nitric oxide independent activation of guanylate cycl ise by YC-1 causes erectile reponses in the rat. J Urol 2002;167:2276-81
91. Stasch JP, Becker EM, Alonso-Alija C, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001;410:212
92. Kalsi JS, Rees RW, Hobbs AJ, et al. BAY 41-2272, a novel nitric oxide independent soluble guanylate cyclise activator, relaxes human and rabbit corpus; cavernosum in vitro. J Urol 2003;169:761-6
93. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for the treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421
94. Cellek S, Moncada S. Nitrergic neurotransmission in the physiology of penile erection and pathophysiology of erectile dysfunction. In: Nitric oxide and the peripheral nervous system. London: Portland Press; 2000. p. 61
95. Christ GJ. K channels as molecular targets for the treatment of erectile dysfunction. J Androl 2002;23:S10-9
96. Spektor M, Rodriguez R. Rosenbaum RS, et al. Potassium channels and human corporeal smooth muscle cell tone: further evidence of the physiological relevance of the Maxi-K channel subtype to the regulation of human corporeal smooth muscle tone in vitro. J Urol 2002;167(6):2628-35
97. Christ GJ. K channels as molecular targets for the treatment of erectile dysfunction. J Androl 2002;23:S10-9
98. Hewawasam P, Fan W, Cook DA, et al. 4-Aryl-3-(mercapto) quinolin-2-ones: novel maxi-K channel opening relaxants of corporal smooth muscle. Bioorg Med Chem Lett 2004;14(17):4479-82
99. Hewawasam P, Fan W, Ding M, et al. 4-Aryl-3-(hydroxyalkyl) quinolin-2-ones; novel maxi-K channel opening relaxants of corporal smooth muscle targeted for erectile dysfunction. J Med Chem 2003;46(14):2819-22
100. Christ GJ, Rehman J, Day N, et al. Intracorporal injection of hSlo cDNA in rars produces physiologically relevant alterations in penile function. Am J Physiol 1998;275:H600-8
101. Melman A, Zhao W, Davies KP, et al. The successful long-term treatment of age related erectile dysfunction with hSlo cDNA in rats in vivo. J Urol 2003;170(1):285-90
102. Lee SW. Physiological roles and properties of potassium channels in corporal smooth muscle. Drugs Today 2000;36(2-3):147-54
103. Garban H, Marquez D, Magee T. Cloning of rat and human inducible penile nitric oxide synthase. Application for gene therapy of erectile dysfunction. Biol Reprod 1997;56:954-63
104. Champion HC, Bivalacqua. TJ, Hyman AL, et al. Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat. Proc Natl Acad Sci USA 1999;96(20):11648-52
105. Bivalacqua TJ, Usta MF, Champion HC, et al. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol 2003;169(5):1911-7
106. Magee TF, Ferrini M, Garban HJ, et al. Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase. Biol Reprod 2002;67(3):1033-41
107. Magee TR, Ferrini MG, Davila HH, et al. Protein inhibitor of nitric oxide synthase (NOS) and the N-methyl-D-aspartate receptor are expressed in the rat and mouse penile nerves and co-localize with penile neuronal NOS. Biol Reprod 2003;68(2):478-88
108. Rogers RS, Graziottin TM, Lin CS, et al. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res 2003;15:26-37.
109. Gonzalez-Cadavid NF, Rajfer J. Therapy of erectile dysfunction: potential future treatments. Endocrine 2004;23(2-3):167-76
110. Chancellor MB, Tirney S, Mattes CE. Nitric oxide synthase gene transfer for erectile dysfunction in a rat model. BJU Int 2003;91:691-6
111. Peel AL, Zolotukhin S, Schrimsher GW, et al. Efficient transduction of green fluorescent protein in spinal card neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther 1997;4:16-24
112. Bennet NE, Kim JH, Yoshimura N. Improvement in erectile dysfunction after neurotrophic factor gene therapy in diabetic rats. J Urol 2005;173(5):1820-4
113. Mitani K, Kubo S. Adenovirus as an integrating vector. Curr Gene Ther 2002;2:135-44
114. Fitzsimons HL, Bland RJ. Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain. Methods 2002;28:227-36
115. Lund PK. The alpha-smooth muscle actin promoter: a useful tool to analyse autocrine and paracrine roles of mesenchymal cells in normal and diseased bowel. 1998;42(3):320-2
116. Famulok M, Verma S. In vivo-applied functional RNAs as tools in proteomics and genomics research. Trends Biotechnol 2002;20:462-8